Inter Partes Review Victory for Celgene -
Quinn Emanuel recently won an inter partes review (“IPR”) of a patent covering the active ingredient in firm client Celgene Corporation’s (“Celgene”) blockbuster cancer therapy, Revlimid®, and certain associated methods of use. Revlimid® is a $5 billion per year product. The United States Patent and Trademark Office’s Patent Trial and Appeal Board’s (“PTAB”) decision provides Celgene with patent certainty until at least late 2019....
Please see full publication below for more information.
